Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies
A partir des données de 3 grandes études " the Collaborative reanalysis", "the Women's Health Initiative" et "the Million Women Study", cette étude analyse l'association entre un traitement hormonal substitutif de la ménopause et le risque de cancer du sein
Background Based principally on findings in three studies, the collaborative reanalysis (CR), the Women's Health Initiative (WHI) and the Million Women Study (MWS), it is claimed that hormone replacement therapy (HRT) with estrogen plus progestogen (E+P) is now an established cause of breast cancer; the CR and MWS investigators claim that unopposed estrogen therapy (ET) also increases the risk, but to a lesser degree than does E+P. The authors have previously reviewed the findings in the CR and WHI (Parts 1–3).Objective To evaluate the evidence for causality in the MWS.Methods Using generally accepted causal criteria, in this article (Part 4) the authors evaluate the findings in the MWS for E+P and for ET.Results Despite the massive size of the MWS the findings for E+P and for ET did not adequately satisfy the criteria of time order, information bias, detection bias, confounding, statistical stability and strength of association, duration-response, internal consistency, external consistency or biological plausibility. Had detection bias resulted in the identification in women aged 50–55 years of 0.3 additional cases of breast cancer in ET users per 1000 per year, or 1.2 in E+P users, it would have nullified the apparent risks reported.Conclusion HRT may or may not increase the risk of breast cancer, but the MWS did not establish that it does.
http://jfprhc.bmj.com/content/early/2012/01/08/jfprhc-2011-100229.abstract